SABCS 2023: Anticipating New Data in HR+/HER2- Breast Cancer

Tarah J. Ballinger, MD

November 27, 2023

In looking forward to the San Antonio Breast Cancer Symposium (SABCS) 2023, Tarah J. Ballinger, MD, anticipates fresh data on HR+/HER2-breast cancer. One highlight is the NATALEE trial's follow-up data on ribociclib, revealing improved disease-free survival in stage II or III ER+/HER2- disease.

Dr Ballinger also looks forward to discussions into potential biomarkers for adjuvant CDK4/6 inhibitors and the role of immunotherapy, especially from the KEYNOTE-756 trial as well as the datopotamab deruxtecan trial results on antibody-drug conjugates. Overall, positive outcomes for patients are expected, with insights on practical applications in breast cancer treatment.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: SABCS 2023: Anticipating New Data in HR+/HER2- Breast Cancer - Medscape - Nov 27, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

SABCS 2023: Anticipating New Data in HR+/HER2- Breast Cancer

Tables

Authors and Disclosures

Authors and Disclosures

Expert

Tarah J. Ballinger, MD

Comments

Email This

Feedback